Prophase Labs

Prophase Labs EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Prophase Labs (PRPH) as of Oct 21, 2026 is -30.14 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -61.12 % — a change of -50.68% (higher).

EBIT/Assets

-30.14 %

YoY

-50.68%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Prophase Labs is 2025 -30.14 % . Operating Income to Assets Ratio (EBIT/Assets) of Prophase Labs was 2024 -61.12 % . It decreases by -50.68% higher compared to the previous year.

The Prophase Labs EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-7.88 USD
Jan 1, 2019
-26.39 USD
Jan 1, 2020
-12.65 USD
Jan 1, 2021
10.98 USD
Jan 1, 2022
26.92 USD
Jan 1, 2023
-23.51 USD
Jan 1, 2024
-61.12 USD
Jan 1, 2025
-30.14 USD
The Prophase Labs EBIT/Assets history
YEAREBIT/AssetsYoY
-30.14 %-50.68%
-61.12 %+159.97%
-23.51 %-187.34%
26.92 %+145.26%
10.98 %-186.76%
-12.65 %-52.06%
-26.39 %+234.90%
-7.88 %-32.54%
-11.68 %-43.70%
-20.75 %-14.16%
-24.17 %-50.42%
-48.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prophase Labs Stock analysis

What does Prophase Labs do? ProPhase Labs, Inc. generates revenue through the sale of over-the-counter consumer healthcare products and dietary supplements. The company develops and markets TK Supplements, featuring LEGENDZ XL for male sexual enhancement, TRIPLE EDGE XL for daily energy and stamina, and SUPER PROSTAFLOW plus for prostate and urinary health. ORXx Complete, a dietary supplement, and ORXx cough/cold drops are also sold to national wholesalers, distributors, and retail chains including pharmacies and mass merchandise stores. The firm targets health-conscious consumers seeking natural solutions through its OTC drug and supplement lines. Its products are distributed via national wholesalers and retailers such as independent and chain drugstores, food stores, and mass merchandise outlets. ProPhase Labs focuses on direct sales to these established retail segments without third-party branding or partnerships. Revenue streams are derived from the consistent demand for male enhancement, energy, and health supplements within the OTC market. The company's product portfolio caters specifically to customers interested in natural health products, with no additional services or digital platforms beyond physical product sales. Prophase Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prophase Labs stock

Operating Income to Assets Ratio (EBIT/Assets) of Prophase Labs is -30.14 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Prophase Labs changed from -61.12 % to -30.14 %, representing a -50.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Prophase Labs since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Prophase Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Prophase Labs

All Key Metrics — Prophase Labs